IP Library Granted Patent US 9,074,263
Granted Patent B2
US 9,074,263 · App. 14/451,263 · Granted Jul 7, 2015

Compositions and reaction mixtures for the detection of nucleic acids from multiple types of human papillomavirus

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,074,263
App. No.
14/451,263
Granted
Jul 7, 2015
Kind
B2
Abstract

Nucleic acid oligonucleotide sequences are disclosed which include amplification oligomers and probe oligomers which are useful for detecting multiple types of human papillomaviruses (HPV) associated with cervical cancer. Methods for detecting multiple HPV types in biological specimens by amplifying HPV nucleic acid sequences in vitro and detecting the amplified products are disclosed.

Claims (11)

1. A combination of amplification oligomers for detecting human papillomavirus (HPV) of multiple HPV types, the combination comprising first amplification oligonucleotides, comprising a target binding region and a 5′ promoter sequence, and second amplification oligonucleotides, comprising a target binding region, wherein pairs of the first and second amplification oligonucleotides can hybridize to opposing strands of HPV nucleic acid for transcription mediated amplification of HPV nucleic acid between hybridized pairs of the first and second amplification oligonucleotides, wherein

(a) the target binding regions of the first amplification oligomers consist of SEQ ID Nos. 19, 21, 23, 25, 29, 31, 33, 35, and 37, respectively, and the target binding regions of the second amplification oligomers consist of SEQ ID Nos. 38, 39, 40, and 41, respectively; or complements thereof; RNA equivalents thereof; or RNA equivalents of the complements thereof; or

(b) the target binding regions of the first amplification oligomers consists of SEQ ID Nos. 21, 23, 25, 29, 31, 33, 35, 37, and 42, respectively, and the target binding regions of the second amplification oligomers consist of SEQ ID Nos. 38, 39, 40, and 41, respectively, or complements thereof; RNA equivalents thereof; or RNA equivalents of the complements thereof.

2. The combination of oligonucleotides of claim 1 , wherein the first amplification oligonucleotides consist of SEQ ID Nos. 18, 20, 22, 24, 28, 30, 32, 34 and 36, respectively.

3. The combination of oligonucleotides of claim 1 , in which one or more individual oligonucleotide sequences include a backbone that includes at least one 2′-methoxy RNA group, at least one 2′ fluoro-substituted RNA group, at least one peptide nucleic acid linkage, at least one phosphorothioate linkage, at least one methylphosphonate linkage or any combination thereof.

4. The combination of oligonucleotides of claim 1 , further comprising at least two probe oligonucleotides wherein each probe oligonucleotide comprises an oligonucleotide sequence selected from SEQ ID Nos. 11 to 17, 44 to 54, and 58, sequences that are completely complementary to SEQ ID Nos. 11 to 17, 44 to 54, and 58, RNA equivalents of SEQ ID Nos. 11 to 17, 44 to 54, and 58, or RNA equivalents of the sequences that are completely complementary to SEQ ID Nos. 11 to 17, 44 to 54, and 58, and wherein each probe oligonucleotide optionally includes a label joined directly or indirectly to the oligonucleotide.

5. The combination of oligonucleotides of claim 4 , wherein the probe oligonucleotide sequences comprise at least one 2′-methoxy RNA group.

6. The combination of oligonucleotides of claim 1 , further comprising at least two oligonucleotides wherein each oligonucleotide sequence is selected from the group consisting of SEQ ID Nos. 1 to 10 and RNA equivalents of the sequences identified by SEQ ID Nos. 1 to 10, and wherein the oligonucleotide sequences consisting of SEQ ID Nos. 2, 4, 6, 8 and 10 optionally include a ligand moiety joined to the oligonucleotide sequence.

7. The combination of oligonucleotides of claim 6 , wherein at least one of the oligonucleotide sequences identified by SEQ ID Nos. 1 to 10 comprises at least one 2′-methoxy RNA group, at least one 2′ fluoro-substituted RNA group, at least one peptide nucleic acid linkage, at least one phosphorothioate linkage, or at least one methylphosphonate linkage.

8. An amplification reaction mixture containing amplification oligomers comprising sequences that consist of the sequences of claim 1 .

9. An amplified product detection reaction mixture comprising the oligonucleotide combination of claim 4 .

Assignments (4)
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE R/F 034289 0249 Recorded Jul 17, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 036127/0185 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2015
From: NORMAN, SYLVIA A.; BUNGO, JENNIFER J.; HANNA, WILLIAM L.; RAO, NEERAJ P.
To: GEN-PROBE INCORPORATED
Reel/Frame 035412/0752 →
SECURITY INTEREST Recorded Dec 1, 2014
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 034289/0249 →